Development and Market Objectives

- Development of novel recombinant human hyaluronidase which can facilitate of large volume subcutaneous drug delivery esp. for immunoglobulins and anti-cancer monoclonal antibody therapeutics by degrading hyaluronan and promoting dispersion and absorption of administered fluid

- Improved structural stability and enzymatic activity by modifying human hyaluronidase PH20.

Unmet Medical Need & Target Patients

-  Applicable to any protein/antibody therapeutics which could be developed for SC administration

-  More emphasis on patient convenience in recent therapeutics market

-  SC administration is predominantly preferred to IV administration in terms of treatment time, cost, and patient convenience.

Current Progress

- Stable cell line was established.

- Production process development for large scale production is ongoing.

- Preclinical animal study will soon be initiated.

Intellectual Property

- Patent #: 10-2018-00***** (application date: 2018. 07. 25)

- Patent #: 10-2019-00***** (application date: 2019. 03. 15)

Competitive Advantages

- Higher specific activity, stability and productivity than the wild-type PH20 and rHuPH20

- The only second recombinant human hyaluronidases in the market

Disease Target

Others

Project duration

2019.07.01-2020.06.30

Organization

Alteogen Inc.

Phase of Development

Non-clinical

Contact

• Organization: Alteogen Inc.
• Website: http://www.alteogen.com
• Contact Person: Sunbae Lee
• E-mail: sblee@alteogen.com
• Phone No.: +82-42-867-8783

Related Projects